ArticleAdvances in therapy2026
A Discrete Choice Experiment of Clinician Preferences Among Attributes of Approved Janus Kinase Inhibitors for Alopecia Areata.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAs the treatment landscape for alopecia areata (AA) expands, it is crucial to understand how treatment properties impact clinician decision-making. The objective of the study was to understand how clinicians treating AA make decisions and evaluate the relative importance (RI) of treatment attributes.
methodsAn online discrete choice experiment (DCE) was conducted among clinicians treating AA recruited through M3 Global Research's US panel from February to March 2024. Treatment selection was evaluated using a series of 10 hypothetical binary choices. Preference weights from the DCE were estimated from conditional logistic regression models and were used to calculate willingness to trade off and attributes' RI. For preference of prescription drug profile, clinicians chose among three blinded profiles of Janus kinase (JAK) inhibitor treatments approved for use in AA based on data from phase 2b-3 pivotal studies. Drug profile A was based on baricitinib 4-mg data, profile B on ritlecitinib 50-mg data, and profile C on deuruxolitinib 8-mg data. These blinded profiles were ranked as most and least preferred.
resultsOf the 249 screened clinicians, 155 were eligible for analysis (129 dermatologists, 15 physician assistants, and 11 nurse practitioners). Clinicians were predominantly White (75.5%) and male (57.4%), with a mean age of 47.3 years. Approximately 50% of the clinicians had been practicing for over 15 years, and the majority were in office-based practices (82%), seeing a mean of 38.8 patients with AA per month. The RI in decreasing order was scalp hair regrowth (52.7%), initial hair growth (31.5%), and medication frequency (15.8%). For the blinded treatment profiles, drug profile C was most preferred (72.2%) and drug profile B was least preferred (81.9%).
conclusionOur study demonstrated that, regarding JAK inhibitor treatment of AA, clinicians preferred options with higher efficacy and shorter time to onset regardless of once-daily or twice-daily dosing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.